Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Weighted Average) (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $28.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.23% to $28.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.9 million through Dec 2025, up 1.23% year-over-year, with the annual reading at $28.9 million for FY2025, 1.23% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $28.9 million in Q4 2025 for Krystal Biotech, roughly flat from $29.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $29.0 million in Q3 2025 to a low of $21.3 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $26.2 million across 5 years, with a median of $26.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 18.17% in 2022 and later grew 0.83% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $22.2 million in 2021, then increased by 14.85% to $25.5 million in 2022, then increased by 6.52% to $27.2 million in 2023, then increased by 5.3% to $28.6 million in 2024, then grew by 1.23% to $28.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KRYS at $28.9 million in Q4 2025, $29.0 million in Q3 2025, and $28.9 million in Q2 2025.